Press Announcements > FDA approves two hepatitis C drugs for pediatric patients

Press Announcements > FDA approves two hepatitis C drugs for pediatric patients

FDA approves two hepatitis C drugs for pediatric patients

04/07/2017 10:27 AM EDT

The U.S. Food and Drug Administration today approved supplemental applications for Sovaldi (sofosbuvir) and Harvoni (ledipasvir and sofosbuvir) to treat hepatitis C virus (HCV) in children ages 12 to 17. Harvoni and Sovaldi were previously approved to treat HCV in adults.